Quick Answer
TELA Bio, Inc. reported Long Term Debt of $55.65 million for the year ending 2025.
- TELA Bio, Inc. showed an increase of +35.3% in Long Term Debt from 2024 to 2025.
- This data is from TELA Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $30.38 million | Q2 2020: $30.52 million | Q3 2020: $30.67 million | Q1 2021: $30.98 million | Q2 2021: $31.15 million | Q3 2021: $31.32 million | Q4 2021: $31.49 million | Q1 2022: $31.67 million | Q2 2022: $39.62 million | Q3 2022: $39.77 million | Q1 2023: $40.06 million | Q2 2023: $40.21 million | Q3 2023: $40.36 million | Q1 2024: $40.67 million | Q2 2024: $40.82 million | Q3 2024: $40.97 million | Q1 2025: $41.28 million | Q2 2025: $38.05 million | Q3 2025: $41.49 million.
- Over the full 7 years of available data (2019 to 2025), TELA Bio, Inc.'s Long Term Debt has grown by 84.0%.
- Historical annual values: Fiscal year 2025: $55.65 million | Fiscal year 2024: $41.12 million | Fiscal year 2023: $40.52 million | Fiscal year 2022: $39.92 million | Fiscal year 2021: $31.49 million | Fiscal year 2020: $30.83 million | Fiscal year 2019: $30.24 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: